Semaglutide kidney disease evidence leads the GLP 1 class while tirzepatide data stay early

A new evidence review from News-Medical sets out how strong the case for semaglutide kidney disease protection really is, and how quickly it weakens for the rest of the GLP-1 class. Published on 27 October 2026, the review finds the firmest proof in semaglutide's dedicated kidney outcome trial, while most other signals come from secondary endpoints, pooled data or albumin in the urine. This is not a new trial result. It is a map of what has been shown, what is only suggested and what has not yet been tested.

What the FLOW trial proved for semaglutide

The FLOW trial is the anchor. It was a double blind kidney outcome study in people with type 2 diabetes and albuminuric chronic kidney disease, and it tested once weekly semaglutide against placebo. According to the review, the drug cut the relative risk of the primary composite by 24%. Three kinds of event counted toward it: kidney failure, a lasting fall in estimated glomerular filtration rate (eGFR) to half the starting level or lower, and death from cardiovascular or kidney causes. Kidney failure meant long term dialysis or transplant, or an eGFR that stayed under 15 mL/min/1.73 m². Trade reports put enrollment at 1,767 adults on semaglutide and 1,766 on placebo, and HCPLive noted that the trial stopped early after meeting its efficacy criteria.

That result became a label. The FDA approved Ozempic on 28 January 2025 to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, as CNBC reported at the time. Kidney News, the American Society of Nephrology magazine, reported that EU regulators also widened the semaglutide indication. So in this one population, semaglutide kidney disease protection is an approved use rather than a hypothesis. On our board, semaglutide does not move, because it was already approved and the review adds no new data. What the review does is set the older trials beside FLOW, and that shows how much of the class case rests on a single study.

Albuminuria falls but kidney failure is a harder test

Most of the class evidence rests on albuminuria, the leak of albumin into urine that marks kidney injury and predicts both kidney decline and heart risk. Meta-analyses cited in the News-Medical review report that GLP-1 receptor agonists lower the urinary albumin to creatinine ratio (UACR). The catch is that a lower UACR is related to, but separate from, keeping filtration intact. The review says plainly that a fall in albuminuria alone does not show that kidney failure has been prevented. It also flags one meta-analysis that found bigger UACR cuts in early CKD, stages 1 and 2, compared with stages 3 to 5, a contrast built on only three studies with different patients and treatments.

The review says plainly that a fall in albuminuria alone does not show that kidney failure has been prevented.

The pooled numbers show both the gain and its size. One meta-analysis of nine randomized trials with 21,717 participants, mostly with type 2 diabetes, found 16% fewer major adverse kidney events and 17% lower all cause mortality versus placebo or standard care. A second found a 12% lower risk of substantial kidney function decline across nine trials and 34,100 people. Its eGFR slope analysis, covering 16 trials and 30,538 participants, found yearly filtration loss slowed by an average of 0.45 mL/min/1.73 m² versus comparators, with wide spread between studies. These are real but modest effects, and the review warns that semaglutide kidney disease results should not be assumed for every drug in the class.

Tirzepatide kidney data and patients without diabetes

The review argues that glucose control cannot explain the whole kidney effect, because signals also appear in people without diabetes. In SELECT, semaglutide lowered a prespecified composite kidney endpoint by 22% in adults with overweight or obesity and established cardiovascular disease. That composite included persistent macroalbuminuria, so it is not a 22% cut in kidney failure. Among SELECT participants whose starting eGFR was under 60, the eGFR change favored semaglutide by 2.19 mL/min/1.73 m² at 104 weeks. Another trial, in adults carrying excess weight who had chronic kidney disease but no diabetes, found UACR 52.1% lower than placebo at 24 weeks, a short result about albumin rather than dialysis.

For tirzepatide kidney evidence, the picture is earlier. In a post hoc analysis of SURPASS-4, the GLP-1 and GIP dual agonist slowed annual eGFR decline by 2.2 mL/min/1.73 m² compared with insulin glargine. Pooled SURPASS data showed UACR falling with dose, by up to 47.3% at the highest dose in people who already had raised albuminuria at the start. The review says these findings justify more study but do not yet show an effect on kidney failure. Combination data are weaker still, since an EXSCEL post hoc analysis tied exenatide plus an SGLT2 inhibitor to slower eGFR decline without randomizing SGLT2 use. Our retatrutide kidney trial coverage shows a similar split between albuminuria and measured filtration.

Where the kidney evidence runs thin

The gaps are specific. High certainty randomized evidence is limited in advanced CKD, especially stage 5 and people on dialysis, the review says. Some trials enrolled stage 4 patients, but their numbers and outcome reporting were incomplete. The authors want longer studies that track kidney failure in non diabetic patients, above all those without obesity, plus purpose built trials of tirzepatide and of drug combinations. Tolerability is the practical limit, because these drugs raise gastrointestinal side effects that lead some patients to stop early. That matters for a benefit that builds over years. Proposed mechanisms, from a systolic blood pressure drop of about 3 to 5 mmHg to sodium excretion and anti-inflammatory effects seen in lab work, remain uncertain contributors.

Context helps here, since these drugs join an existing regimen. Chronic kidney disease affected an estimated 9.1% of the world's population in 2017, according to the review, and blood pressure control plus renin angiotensin system blockade remain standard care, with SGLT2 inhibitors alongside. GLP-1 drugs are being tested as an added layer, not a replacement. Our earlier Kidney Week evidence review found the same thin spots in dialysis and transplant care. A separate CKD awareness gap analysis found that most eligible US adults with type 2 diabetes do not know they have kidney disease. None of this is medical advice, and treatment choices belong with a clinician who knows the patient's kidney history.

Conclusion

The review moves no molecule on our board, but it sets a clear bar. For semaglutide kidney disease protection in type 2 diabetes with albuminuric CKD, FLOW supplies hard outcome proof and an approved US indication. Elsewhere, from obesity without diabetes to tirzepatide and dialysis, the data mostly track albuminuria or eGFR slope. The next real test is a dedicated kidney outcome trial that counts kidney failure in those groups.